Canadian boreal forests and climate change mitigation von Lemprière, T.C., Kurz, W.A., Hogg, E.H., Schmoll, C., Rampley, G.J., Yemshanov, D., McKenney, D.W., Gilsenan, R., Beatch, A., Blain, D., Bhatti, J.S., Krcmar, E.

Volltext

Use of the QuantiFERON®-TB Gold test to confirm latent tuberculosis infection in a Canadian tuberculosis clinic von KUNIMOTO, D, DER, E, LONG, R, BECKON, A, THOMAS, L, EGEDAHL, M, BEATCH, A, WILLIAMS, G, TYRRELL, G, AHMED, R, BROWN, N

Volltext

A Randomized Active-Controlled Study Comparing the Efficacy and Safety of Vernakalant to Amiodarone in Recent-Onset Atrial Fibrillation von Camm, A. John, MD, Capucci, Alessandro, MD, Hohnloser, Stefan H., MD, Torp-Pedersen, Christian, MD, Van Gelder, Isabelle C., MD, Mangal, Brian, MSc, Beatch, Gregory, PhD

Volltext

Spontaneous and TMS-related EEG changes as new biomarkers to measure anti-epileptic drug effects von Biondi, Andrea, Rocchi, L., Santoro, V., Rossini, P. G., Beatch, G. N., Richardson, M. P., Premoli, I.

Volltext

The Mechanism of Atrial Antiarrhythmic Action of RSD1235 von FEDIDA, DAVID, ORTH, PETER M.R., CHEN, JANET Y.C., LIN, SHUNPING, PLOUVIER, BERTRAND, JUNG, GRACE, EZRIN, ALAN M., BEATCH, GREGORY N.

Volltext

A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation von Roy, Denis, Rowe, Brian H., Stiell, Ian G., Coutu, Benoit, Ip, John H., Phaneuf, Denis, Lee, Jacques, Vidaillet, Humberto, Dickinson, Garth, Grant, Sheila, Ezrin, Alan M., Beatch, Gregory N.

Volltext

Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial von Beatch, Gregory N, Mangal, Brian

Volltext

Efficacy and safety of vernakalant for cardioversion of recent-onset atrial fibrillation in the Asia–Pacific region: a phase 3 randomized controlled trial von Beatch, Gregory N, Bhirangi, Kiran, Juul-Moller, Steen, Rustige, Jörg

Volltext

Stabilizing Dog Populations and Improving Animal and Public Health Through a Participatory Approach in Indigenous Communities von Schurer, J. M., Phipps, K., Okemow, C., Beatch, H., Jenkins, E.

Volltext

Assessment of Potential Pharmacokinetic and Pharmacodynamic Interactions between XEN901 (a Novel NaV1.6 Selective Sodium Channel Blocker) and Phenytoin (a non-selective NaV Blocker... von Namdari, Rostam, Beatch, Gregory N., Cadieux, Jay A., Aycardi, Ernesto

Volltext

Pharmacokinetic and Food Effect Assessment of XEN496 (Pediatric Formulation of Ezogabine) in Healthy Adults and Relative Bioavailability Assessment with Potiga® (Adult Formulation... von Cadieux, Jay A., Namdari, Rostam, Beatch, Gregory N., Aycardi, Ernesto

Volltext

Relative bioavailability, pharmacokinetic and food effect assessment of two immediate-release formulations of the NaV1.6-selective sodium channel blocker XEN901: Pediatric Granules... von Namdari, Rostam, Beatch, Gregory N., Cadieux, Jay A., Aycardi, Ernesto

Volltext

A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of Two Formulations of a Novel Nav1.6 Sodium Channnel Blocker (XEN901) in Healthy Adult Subjects. (4757) von Beatch, Gregory, Namdari, Rostam, Cadieux, Jay, Kato, Heather, Aycardi, Ernesto

Volltext

The Impact of Disease Severity on Responder Rates in a Phase 2b Study of XEN1101, a Potent, Selective Potassium Channel Opener, in Adults with Focal Epilepsy (X-TOLE) (S19.004) von Porter, Roger, French, Jacqueline, Perucca, Emilio, Brodie, Martin, Harden, Cynthia, Rosenblut, Constanza Luzon, Qian, Jenny, Kenney, Christopher, Beatch, Gregory

Volltext

Children’s understanding of additive concepts von Robinson, Katherine M., Dubé, Adam K., Beatch, Jacqueline-Ann

Volltext

TMS as a pharmacodynamic indicator of cortical activity of a novel anti‐epileptic drug, XEN1101 von Premoli, Isabella, Rossini, Pierre G., Goldberg, Paul Y., Posadas, Kristina, Green, Louise, Yogo, Noah, Pimstone, Simon, Abela, Eugenio, Beatch, Gregory N., Richardson, Mark P.

Volltext

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Safety and Efficacy of XEN1101 as an Adjunctive Therapy in the Treatment of Primary Generalized Tonic-C... von Gil-Nagel, Antonio, Vossler, David, Ben-Menachem, Elinor, LaFrance, W., Harden, Cynthia, Qian, Jenny, Beatch, Gregory, Kenney, Christopher

Volltext

Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial von French, Jacqueline A, Porter, Roger J, Perucca, Emilio, Brodie, Martin J, Rogawski, Michael A, Pimstone, Simon, Aycardi, Ernesto, Harden, Cynthia, Qian, Jenny, Luzon Rosenblut, Constanza, Kenney, Christopher, Beatch, Gregory N

Volltext

Interim Long-term Safety and Efficacy of XEN1101, a Potent, Selective Potassium Channel Opener: Update from an Ongoing Open-label Extension of a Phase 2b Study (X-TOLE) in Adults w... von French, Jacqueline, Porter, Roger, Perucca, Emilio, Brodie, Martin, Rogawski, Michael, Harden, Cynthia, Qian, Jenny, Rosenblut, Constanza Luzon, Kenney, Christopher, Beatch, Gregory

Volltext

Pharmacokinetics of XEN496, a Novel Pediatric Formulation of Ezogabine, Under Fed and Fasted Conditions: A Phase 1 Trial von Namdari, Rostam, Luzon, Constanza, Cadieux, Jay A., Leung, Jennifer, Beatch, Gregory N.

Volltext